Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis

Hein, 2000, Update on consensus N-acetyltransferase gene nomenclature, Pharmacogenetics, 10, 291, 10.1097/00008571-200006000-00002 Hein, 1991, A new model for toxic risk assessments: construction of homozygous rapid and slow acetylator congenic Syrian hamster lines, Toxicol. Methods, 1, 44, 10.3109/15376519109036524 Hein, 1994, Construction of Syrian hamster lines congenic at the polymorphic acetyltransferase locus (NAT2): acetylator genotype-dependent N- and O-acetylation of arylamine carcinogens, Toxicol. Appl. Pharmacol., 124, 16, 10.1006/taap.1994.1003 Leff, 1999, Prostate-specific human N-acetyltransferase 2 (NAT2) expression in the mouse, J. Pharmacol. Exp. Ther., 290, 182 Hein, 1991, Extrahepatic expression of the N-acetylation polymorphism towards arylamine carcinogens in tumor target organs of an inbred rat model, J. Pharmacol. Exp. Ther., 258, 232 Hein, 1991, Polymorphic and monomorphic expression of arylamine carcinogen N-acetyltransferase isozymes in tumor target organ cytosols of Syrian hamsters congenic at the polymorphic acetyltransferase locus, J. Pharmacol. Exp. Ther., 259, 699 Feng, 1996, 3,2′-Dimethyl-4-aminobiphenyl-DNA adduct formation in tumor-target and non-target organs of rapid and slow acetylator Syrian hamsters congenic at the NAT2 locus, Toxicol. Appl. Pharmacol., 140, 315, 10.1006/taap.1996.0226 Jiang, 1999, Higher DNA adduct levels in urinary bladder and prostate of slow acetylator inbred rats administered 3,2′-dimethyl-4-aminobiphenyl, Toxicol. Appl. Pharmacol., 156, 187, 10.1006/taap.1998.8621 Shirai, 1997, The prostate: a target for carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) derived from cooked foods, Cancer Res., 57, 195 Shirai, 1999, Carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in the rat prostate and induction of invasive carcinomas by subsequent treatment with testosterone propionate, Cancer Lett., 143, 217, 10.1016/S0304-3835(99)00128-7 Feng, 1996, Acetylator genotype (NAT2)-dependent formation of aberrant crypts in congenic Syrian hamsters administered 3,2′-dimethyl-4-aminobiphenyl, Cancer Res., 56, 527 Paulsen, 1996, Effect of acetylator genotype on 3,2′-dimethyl-4-aminobiphenyl induced aberrant crypt foci in the colon of hamsters, Carcinogenesis, 17, 459, 10.1093/carcin/17.3.459 Feng, 1997, Higher frequency of aberrant crypt foci in rapid than slow acetylator inbred rats administered the colon carcinogen 3,2′-dimethyl-4-aminobiphenyl, Toxicol. Appl. Pharmacol., 147, 56, 10.1006/taap.1997.8259 Purewal, 2000, 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine induces a higher number of aberrant crypt foci in Fischer 344 (rapid) than Wistar Kyoto (slow) acetylator rats, Cancer Epidemiol. Biomarkers Prev., 9, 529 Fretland, 2001, Functional characterization of nucleotide polymorphisms in the coding region of human N-acetyltransferase 1, Pharmacogenetics, 11, 511, 10.1097/00008571-200108000-00006 A.J. Fretland, M.A. Doll, Y. Zhu, L. Smith, M.A. Leff, D.W. Hein, Effect of nucleotide substitutions in N-acetyltransferase-1 on N-acetylation (deactivation) and O-acetylation (activation) of arylamine carcinogens: implications for cancer predisposition, Cancer Detect. Prev. 26 (2002) 10–14. Bell, 1995, Polymorphism in the N-acetyltransferase 1 polyadenylation signal: association of NAT1∗10 allele with higher N-acetylation activity in bladder and colon tissue, Cancer Res., 55, 5226 Hein, 2000, Pharmacogenetics of the arylamine N-acetyltransferases: a symposium in honor of Wendell W. Weber, Drug Metab. Dispos., 28, 1425 Hein, 2000, Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms, Cancer Epidemiol. Biomarkers Prev., 9, 29 de Leon, 2000, Characterization of naturally occurring and recombinant human N-acetyltransferase variants encoded by NAT1, Mol. Pharmacol., 58, 288, 10.1124/mol.58.2.288 Butcher, 2000, Substrate-dependent regulation of human arylamine N-acetyltransferase-1 in cultured cells, Mol. Pharmacol., 57, 468, 10.1124/mol.57.3.468 Weber, 1985, N-Acetylation pharmacogenetics, Pharmacol. Rev., 37, 25 Fretland, 2001, Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms, Pharmacogenetics, 11, 207, 10.1097/00008571-200104000-00004 Y. Zhu, M.A. Doll, D.W. Hein, Functional genomics of C190T single nucleotide polymorphism in human N-acetyltransferase 2, Biol. Chem. 383 (2002) 983–987. Hein, 1995, Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions, Cancer Res., 55, 3531 Brockmoller, 1996, Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione-S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk, Cancer Res., 56, 3915 Okkels, 1997, Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking, Cancer Epidemiol. Biomarkers Prev., 6, 225 Filiadis, 1999, Genotypes of N-acetyltransferase-2 and risk of bladder cancer: a case-control study, J. Urol., 161, 1672, 10.1016/S0022-5347(05)69002-7 Cartwright, 1982, Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer, Lancet, 2, 842, 10.1016/S0140-6736(82)90810-8 D.W. Hein, M.A. Leff, N. Ishibe, R. Sinha, J. Berlot, J. Frame, H.A. Frazier, M.A. Doll, M.C. Weinrich, N.E. Caporaso, Slow N-acetyltransferase and null glutathione-S-transferase genotypes and prostate cancer risk, in: Proceedings of the Joint Meeting of the American Society for Biochemistry and Molecular Biology/American Society for Pharmacology and Experimental Therapeutics, #LB64, Boston, MA, June 2000. D.W. Hein, M.A. Leff, N. Ishibe, R. Sinha, H.A. Frazier, M.A. Doll, G.H. Xiao, M.C. Weinrich, N.E. Caporaso, Association of prostate cancer with rapid N-acetyltransferase 1 (NAT1∗10) in combination with slow N-acetyltransferase 2 genotypes in a pilot case control study. Environ. Mol Mutagen. 40 (2002) in press. Taylor, 1998, The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene–gene exposure three-way interaction, Cancer Res., 58, 3603 Cascorbi, 2001, Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1∗10, Cancer Res., 61, 5051 Hein, 2000, N-Acetyltransferase genetics and their role in predisposition to aromatic and heterocyclic amine-induced carcinogenesis, Toxicol. Lett., 112/113, 349, 10.1016/S0378-4274(99)00226-X Brockton, 2000, N-Acetyltransferase polymorphisms and colorectal cancer: a HuGE review, Am. J. Epidemiol., 151, 846, 10.1093/oxfordjournals.aje.a010289 Ishibe, 2002, Genetic polymorphisms in heterocyclic amine metabolism and risk of colorectal adenomas, Pharmacogenetics, 12, 145, 10.1097/00008571-200203000-00008 Sinclair, 2000, Structure of arylamine N-acetyltransferase reveals a catalytic triad, Nat. Struct. Biol., 7, 560, 10.1038/76783 Lima-Rodrigues, 2001, Homology modelling and structural analysis of human arylamine N-acetyltransferase NAT1: evidence for the conservation of a cysteine protease catalytic domain and an active-site loop, Biochem. J., 356, 327, 10.1042/0264-6021:3560327 Lima-Rodrigues, 2002, 3D model of human arylamine N-acetyltransferase 2: structural basis of the slow acetylator phenotype of the R64Q variant and analysis of the active-site loop, Biochem. Biophys. Res. Commun., 291, 116, 10.1006/bbrc.2002.6414